Supplemental material
Human Vaccines & Immunotherapeutics
Volume 16, 2020 - Issue 6
Research Paper
Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
Dan Bia GSK, Wavre, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0003-0426-4639View further author information
https://orcid.org/0000-0003-0426-4639View further author information, , , , , Silvia Damasoa GSK, Wavre, Belgiumhttps://orcid.org/0000-0003-4851-4396View further author information
https://orcid.org/0000-0003-4851-4396View further author information, , , & Frank Struyfa GSK, Wavre, Belgiumhttps://orcid.org/0000-0001-9988-0260View further author information
https://orcid.org/0000-0001-9988-0260View further author information show allRelated Research Data
Review: Current trends in inflammatory bowel disease: the natural history:
Source:
SAGE Publishing
Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
Source:
Informa UK Limited
Safety of vaccine adjuvants: focus on autoimmunity.
Source:
Published by Elsevier Ltd.
Quality of the Finnish Hospital Discharge Register: a systematic review.
Source:
SAGE Publications
Are adverse events after carotid endarterectomy reported comparable in different registries
Source:
The Society for Vascular Surgery. Published by Elsevier Inc.
The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland
Source:
Elsevier BV
Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity
Source:
Elsevier BV
Linking provided by
